

Esther Calbo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1317116/publications.pdf>

Version: 2024-02-01

43
papers

2,608
citations

304743

22
h-index

243625

44
g-index

47
all docs

47
docs citations

47
times ranked

3682
citing authors

#	ARTICLE	IF	CITATIONS
1	Mortality After Hospitalization for COPD. <i>Chest</i> , 2002, 121, 1441-1448.	0.8	582
2	Risk factors for community-onset urinary tract infections due to <i>Escherichia coli</i> harbouring extended-spectrum β -lactamases. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 780-783.	3.0	261
3	An international multicenter retrospective study of <i>Pseudomonas aeruginosa</i> nosocomial pneumonia: impact of multidrug resistance. <i>Critical Care</i> , 2015, 19, 219.	5.8	209
4	Influence of Virulence Genotype and Resistance Profile in the Mortality of <i>Pseudomonas aeruginosa</i> Bloodstream Infections. <i>Clinical Infectious Diseases</i> , 2015, 60, 539-548.	5.8	153
5	A Multinational, Preregistered Cohort Study of β -Lactam/ β -Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum- β -Lactamase-Producing Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4159-4169.	3.2	137
6	Effect of Adequate Single-Drug vs Combination Antimicrobial Therapy on Mortality in <i>Pseudomonas aeruginosa</i> Bloodstream Infections: A Post Hoc Analysis of a Prospective Cohort. <i>Clinical Infectious Diseases</i> , 2013, 57, 208-216.	5.8	135
7	Prospective Multicenter Study of the Impact of Carbapenem Resistance on Mortality in <i>Pseudomonas aeruginosa</i> Bloodstream Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1265-1272.	3.2	123
8	Foodborne Nosocomial Outbreak of SHV1 and CTX-M-15-producing <i>Klebsiella pneumoniae</i> : <i>Epidemiology and Control</i> . <i>Clinical Infectious Diseases</i> , 2011, 52, 743-749.	5.8	112
9	Of mice and men: innate immunity in pneumococcal pneumonia. <i>International Journal of Antimicrobial Agents</i> , 2010, 35, 107-113.	2.5	59
10	The changing epidemiology of hospital outbreaks due to ESBL-producing <i>Klebsiella pneumoniae</i> : the CTX-M-15 type consolidation. <i>Future Microbiology</i> , 2015, 10, 1063-1075.	2.0	55
11	Capsular Types and Predicting Patient Outcomes in Pneumococcal Bacteremia. <i>Clinical Infectious Diseases</i> , 2007, 45, 52-54.	5.8	45
12	Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β -Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort. <i>Clinical Infectious Diseases</i> , 2017, 65, 1615-1623.	5.8	43
13	Community-acquired pneumonia. <i>Lancet</i> , The, 2008, 371, 455-458.	13.7	41
14	Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1672-1680.	3.0	41
15	Procalcitonin levels are lower in intensive care unit patients with H1N1 influenza A virus pneumonia than in those with community-acquired bacterial pneumonia. A pilot study. <i>Journal of Critical Care</i> , 2011, 26, 201-205.	2.2	38
16	Systemic Expression of Cytokine Production in Patients with Severe Pneumococcal Pneumonia: Effects of Treatment with a β -Lactam versus a Fluoroquinolone. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2395-2402.	3.2	37
17	<i>Pseudomonas aeruginosa</i> Nosocomial Pneumonia: Impact of Pneumonia Classification. <i>Infection Control and Hospital Epidemiology</i> , 2015, 36, 1190-1197.	1.8	34
18	ESGAP inventory of target indicators assessing antibiotic prescriptions: a cross-sectional survey. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2910-2914.	3.0	32

#	ARTICLE	IF	CITATIONS
19	The impact of time on the systemic inflammatory response in pneumococcal pneumonia. <i>European Respiratory Journal</i> , 2010, 35, 614-618.	6.7	30
20	A review of the factors influencing antimicrobial prescribing. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2013, 31, 12-15.	0.5	25
21	Impact of vaccination on invasive pneumococcal disease in adults with focus on the immunosuppressed. <i>Journal of Infection</i> , 2015, 71, 422-427.	3.3	24
22	Molecular characterisation of acquired and overproduced chromosomal blaAmpC in <i>Escherichia coli</i> clinical isolates. <i>International Journal of Antimicrobial Agents</i> , 2016, 47, 62-68.	2.5	22
23	Emerging extended-spectrum β -lactamase-producing <i>Klebsiella pneumoniae</i> causing community-onset urinary tract infections: a case-control study. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 197-202.	2.5	21
24	Epidemiology and risk factors for infections due to AmpC β -lactamase-producing <i>Escherichia coli</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 899-904.	3.0	18
25	Risk factors for severe sepsis in community-onset bacteraemic urinary tract infection: Impact of antimicrobial resistance in a large hospitalised cohort. <i>Journal of Infection</i> , 2015, 70, 247-254.	3.3	17
26	Invasive Pneumococcal Disease in Children: Changing Serotypes and Clinical Expression of Disease. <i>Clinical Infectious Diseases</i> , 2005, 41, 1821-1822.	5.8	14
27	Hand contamination during routine care in medical wards: the role of hand hygiene compliance. <i>Journal of Medical Microbiology</i> , 2013, 62, 623-629.	1.8	14
28	Assessment of Quality Indicators for Appropriate Antibiotic Use. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	14
29	High clonal diversity of ESBL-producing <i>Klebsiella pneumoniae</i> isolates from clinical samples in a non-outbreak situation. A cohort study. <i>Antimicrobial Resistance and Infection Control</i> , 2020, 9, 5.	4.1	12
30	Clinical and economic impact of bacterial resistance: an approach to infection control and antimicrobial stewardship solutions. <i>Current Opinion in Infectious Diseases</i> , 2020, 33, 458-463.	3.1	12
31	Application of Pharmacokinetics and Pharmacodynamics to Antimicrobial Therapy of Community-Acquired Respiratory Tract Infections. <i>Respiration</i> , 2005, 72, 561-571.	2.6	11
32	Foreign-Body Osteoarticular Infection by <i>Brucella melitensis</i> : A Report of Three Cases. <i>JBJS Case Connector</i> , 2006, os-88, 202-204.	0.3	11
33	Bacteraemic pneumococcal pneumonia in COPD patients: better outcomes than expected. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2009, 28, 971-976.	2.9	11
34	Factors affecting the development of systemic inflammatory response syndrome in pneumococcal infections. <i>Current Opinion in Infectious Diseases</i> , 2011, 24, 241-247.	3.1	10
35	Genetic susceptibility to invasive pneumococcal disease. <i>Infection, Genetics and Evolution</i> , 2018, 59, 126-131.	2.3	10
36	Related Factors to <i>Streptococcus pneumoniae</i> Invasive Infection and Clinical Manifestations: The Potential Role of Nasopharyngeal Microbiome. <i>Frontiers in Medicine</i> , 2021, 8, 650271.	2.6	9

#	ARTICLE	IF	CITATIONS
37	Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 664-672.	2.5	8
38	Impact of amoxicillin, associated or not with clavulanic acid, on pharyngeal colonization and selection of <i>Streptococcus pneumoniae</i> resistance in children under 5 years of age. <i>European Journal of Pediatrics</i> , 2007, 166, 467-471.	2.7	7
39	Improvement of pneumococcal pneumonia diagnosis using quantitative real-time PCR targeting <i>lytA</i> in adult patients: a prospective cohort study. <i>Clinical Microbiology and Infection</i> , 2022, 28, 138.e1-138.e7.	6.0	5
40	H1N1 influenza pneumonia and bacterial coinfection. <i>Thorax</i> , 2011, 66, 1091-1092.	5.6	2
41	Applicability of Outpatient Quality Indicators for Appropriate Antibiotic Use in a Primary Health Care Area: a Point Prevalence Survey. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	1
42	Applicability of Quality Indicators for Appropriate Antibiotic use in Outpatient Parenteral Antimicrobial Therapy (OPAT): A Point Prevalence Survey. <i>Frontiers in Pharmacology</i> , 2021, 12, 713882.	3.5	1
43	Tromboembolia pulmonar y fiebre prolongada asociada a trombosis del electrodo del marcapasos. <i>Medicina Clínica</i> , 2004, 122, 759-759.	0.6	0